Tempus AI (TEM) Investor Day 2026 summary

Strategic vision and platform overview

• Built a sustainable, integrated ecosystem combining proprietary multimodal healthcare data, advanced AI models, and a broad distribution network, now connected to over 5,000 U.S. institutions and two-thirds of academic medical centers.

• Focused on leveraging AI and multimodal data to transform diagnostics, drug discovery, and patient care, with a proprietary ecosystem integrating diagnostics, data, and applications.

• Embedded EHR integrations and agentic tools streamline clinical workflows and trial matching, enhancing provider and patient experiences.

• Foundation model developed with AstraZeneca and Pathos AI, running on a massive compute cluster, now generating clinically relevant insights at scale, with agentic workflows developed in partnership with leading pharma companies.

• Expansion beyond oncology into rare disease, cardiology, and hereditary profiling, including whole genome sequencing, leveraging acquisitions and partnerships to address unmet diagnostic needs.

Diagnostics business and innovation

• Comprehensive portfolio includes FDA-approved solid tumor and liquid biopsy assays, RNA-based diagnostics, pharmacogenomics, rare disease tests, and AI-driven applications positioned to become reimbursable diagnostic tools.

• Recent FDA approval of xT CDx expands coverage to 100% of DNA portfolio, unlocking significant ASP lift and reimbursement opportunities, with oncology ASPs expected to rise significantly.

• Achieved 28% oncology volume growth in Q1 2026, driven by oncology momentum and expanded hereditary cancer screening capabilities.

• MRD strategy combines best-in-class tumor-informed (Personalis partnership) and in-house tumor-naive assays, with ongoing R&D to improve sensitivity and pan-cancer applicability, expanding clinical utility and market share.

• Hereditary and rare disease segments enhanced by Ambry Genetics integration, with automated platforms targeting large unaffected populations and rapid test turnaround; hereditary testing growth is normalizing with mid-teens trajectory.

Data and applications business

• Data licensing and modeling business is rapidly expanding, working with 19 of the top 20 pharma companies and over 250 biotechs, with $2B+ in cumulative deals and $87M in Q1 revenue, growing at 41% YoY.

• Lens platform enables biopharma clients to build, analyze, and visualize multimodal cohorts, leveraging AI copilots for trial design, biomarker discovery, and real-world evidence.

• Foundation models and agentic platforms are driving new business models, including AI model deployment across pharma pipelines, accelerating insight generation and supporting both internal diagnostics and external pharma R&D.

• Over $2B in contracts signed to date, with $1.1B+ in total remaining contract value as of year-end 2025, and customer base diversifying with rising average value per customer.

• Strategic partnerships with top pharma and biotech companies are expanding, diversifying revenue and embedding solutions across portfolios, with 60+ algorithms deployed in cardiology and oncology and future reimbursement expected.